Osteoporosis in patients with coronary artery disease after coronary bypas surgery

Aim. To determine the most significant predictors of an unfavorable progress of osteoporosis (OP) in men with coronary artery disease after coronary artery bypass grafting (CABG) according to long-term (5 years) follow-up data.

Methods. The prospective study included 393 patients (men) hospitalized for CABG. All patients underwent multispiral computed tomography of the coronary and carotid arteries to assess the calcium score (CS) and determine the equivalent density of calcium deposits (EDCD), coronary angiography, and dual-energy X-ray absorptiometry. After 5 years (average 59 months) of follow-up, the prognosis (status alive/dead) was assessed in 335 patients. Mortality during follow-up in patients after CABG was 10.7% (36 patients died). 257 patients underwent repeated osteodensitometry, quantitative assessment of coronary and carotid calcification, assessment of the “end points” of bone status (osteoporotic fractures, osteoporosis).

Results. During the five-year follow-up an increase in the prevalence of OP was noted from 76.1% to 90.7%, while in 43.6% of cases, the progression of OP was recorded. Fractures occurred in 39 patients (15.2%), and in 34 (13.2%) osteoporosis developed for the first time. OP progression is associated with smoking (OR 5.3, 95% CI 3.1–9.4), 30% or more carotid artery stenosis (OR 5.6, 95% CI 2.9–10.7), baseline severe (more than 400) calcification of the coronary arteries (OR 2.7 at 95% CI 1.3–9.8), low density of (EDCD less than 0.19 g/mm3 ) coronary (OR 1.7 at 95% CI 1.1–8.2) and carotid (OR 2.4, 95% CI 1.4–10.3) calcium deposits. Linear regression analysis made it possible to establish that the reliable predictors of an unfavorable course of OP are coronary CS, EDCD of the carotid arteries, and the absence of statin therapy.

Conclusion. OP progression in patients in the long-term period (5 years) after CABG was noted in 43.6%. The predictors of OP progression and the complications are a high level of coronary artery calcification, a low EDCD in the carotid arteries, and 30% or more stenosis of the carotid arteries. Patients receiving statins were associated with a lower risk of osteoporosis.

1. Radner H., Yoshida K., Smolen J.S., Solomon D.H. Multimorbidity and rheumatic conditions-enhancing the concept of comorbidity. Nat Rev Rheumatol. 2014;10(4):252- 256. doi:10.1038/nrrheum.2013.212

2. Prabhakaran D., Anand S., Watkins D., Gaziano T., Wu Y., Mbanya J.C., Nugent R.; Disease Control Priorities-3 Cardiovascular, Respiratory, and Related Disorders Author Group. Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition. Lancet. 2018;391(10126):1224- 1236. doi:10.1016/S0140-6736(17)32471-6

3. Barnett K., Mercer S.W., Norbury M., Watt G., Wyke S., Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37-43. doi:10.1016/S0140-6736(12)60240-2

4. Ye C., Xu M., Wang S., Jiang S., Chen X., Zhou X., He R. Decreased Bone Mineral Density Is an Independent Predictor for the Development of Atherosclerosis: A Systematic Review and Meta-Analysis. PLoS One. 2016;11(5):e0154740. doi:10.1371/journal.pone.0154740

5. Veronese N., Stubbs B., Crepaldi G., Solmi M., Cooper C., Harvey N.C., Reginster J.Y., Rizzoli R., Civitelli R., Schofield P., Maggi S., Lamb S.E. Relationship Between Low Bone Mineral Density and Fractures With Incident Cardiovascular Disease: A Systematic Review and Meta-Analysis. J Bone Miner Res. 2017;32(5):1126-1135. doi:10.1002/jbmr.3089

6. Kanis J.A., McCloskey E.V., Johansson H., Oden A., Ström O., Borgström F. Development and use of FRAX in osteoporosis. Osteoporos Int. 2010;21(S 2):S407-S413. doi:10.1007/s00198-010-1253-y

7. Kashtalap V.V., Hryachkova O.N., Barbarash O.L. “New” pathological continuum: a hypogonadism, an osteoporosis and the calcinating atherosclerosis. general factors of formation and progression. Ateroscleroz. 2016;12(4):68-78. (In Russian)

8. Masenko V.L., Kokov A.N., Semenov S.E., Barbarash O.L. Non-invasive assessment of the density of calcification of coronary and carotid arteries in patients with type II diabetes mellitus. Vestnik rentgenologii i radiologii. 2019; 99(6): 310-8. (In Russian). doi:10.20862/0042-4676-2018-99-6-310-318

9. Lesnyak O.M., Baranova I.A., Belova K.Yu., Gladkova E.N., Evstigneeva L.P., Ershova O.B., Karonova T.L., Kochish A.Yu., Nikitinskaya O.A., Skripnikova I.A., Toroptsova N.V., Aramisova R.M. Osteoporosis in russian federation: epidemiology, socio-medical and economical aspects. Traumatology and Orthopedics of Russia. 2018;24(1):155-168. (In Russian) doi: 10.21823/2311-2905-2018-24-1-155-168

10. Polyakova J.V., Sivordova L.E., Guryanova E.A., Zavodskiy B.V., Shamitova E.N. Male osteoporosis - medical or social problem? Modern problems of science and education. 2019;1:53. Available at: http://www.science-education.ru/ru/article/view?id=28556 (accessed 28.07.2020) (In Russian)

11. Lin M.E., Chen T.M., Wallingford M.C. Nguyen N.B., Yamada S., Sawangmake C., Zhang J., Speer M.Y., Giachelli C.M. Runx2 deletion in smooth muscle cells inhibits vascular osteochondrogenesis and calcification but not atherosclerotic lesion formation. Cardiovasc Res. 2016;112(2):606-616. doi:10.1093/cvr/cvw205

12. Barbarash O.L., Lebedeva N.B., Kokov A.N., Novitskaya A.A., Hryachkova O.N., Voronkina A.V., Raskina T.A., Kashtalap V.V., Kutikhin A.G., Shibanova I.A. Decreased Cathepsin K Plasma Level may Reflect an Association of Osteopoenia/ Osteoporosis with Coronary Atherosclerosis and Coronary Artery Calcification in Male Patients with Stable Angina. Heart, Lung and Circulation. 2016;25(7):691–7. doi: 10.1016/j.hlc.2016.02.002

13. Barbarash O.L., Kashtalap V.V., Zykov M.V., Novitskaya A.A., Hryachkova O. N., Kokov A. N., Voronkina A.V., Shibanova I.A., Raskina T.A. Аssociation of osteopontin level with coronary atherosclerosis and osteoporosis in male patients with stable coronary artery disease. The Journal of Atherosclerosis and Dyslipidemias. 2016;4(25):40–8. (In Russian)

14. Watts N.B., Adler R.A., Bilezikian J.P., Drake M.T., Eastell R., Orwoll E.S., Finkelstein J.S.; Endocrine Society. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(6):1802-1822. doi:10.1210/jc.2011-3045

15. Barbarash O.L., Davidovich I.M., Pomeshkina S.A., Marenin S.N. Erectile dysfunction in young and middle aged men with arterial hypertension and coronary heart disease. Kemerovo: “Kuzbassvuzizdat”; 2015.142 p. (In Russian)

16. Jutberger H., Lorentzon M., Barrett-Connor E., Johansson H., Kanis J.A., Ljunggren O., Karlsson M.K., Rosengren B.E., Redlund-Johnell I., Orwoll E., Ohlsson C., Mellström D. et al. Smoking predicts incident fractures in elderly men: Mr OS Sweden. J Bone Miner Res. 2010;25(5):1010-1016. doi:10.1359/jbmr.091112

17. Kanis J., Johnell O., Gullberg B., Allander E., Elffors L., Ranstam J., Dequeker J., Dilsen G., Gennari C., Vaz A.L., Lyritis G., Mazzuoli G., Miravet L., Passeri M., Perez Cano R., Rapado A., Ribot C. Risk factors for hip fracture in men from southern Europe: the MEDOS study. Mediterranean Osteoporosis Study. Osteoporos Int. 1999;9(1):45-54. doi:10.1007/s001980050115

18. An T., Hao J., Sun S., Li R., Yang M., Cheng G., Zou M. Efficacy of statins for osteoporosis: a systematic review and meta-analysis. Osteoporos Int. 2017;28(1):47-57. doI:10.1007/s00198-016-3844-8

19. Oryan A., Kamali A., Moshiri A. Potential mechanisms and applications of statins on osteogenesis: Current modalities, conflicts and future directions. J Control Release. 2015;215:12- 24. doi:10.1016/j.jconrel.2015.07.022

20. Tsubaki M., Satou T., Itoh T., Imano M., Yanae M., Kato C., Takagoshi R., Komai M., Nishida S. Bisphosphonate- and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2. Mol Cell Endocrinol. 2012;361(1-2):219-231. doi:10.1016/j.mce.2012.05.002

21. Yeam C.T., Chia S., Tan H.C.C., Kwan Y.H., Fong W., Seng J.J.B. A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporosis Int. 2018;29:2623-37. doi: 10.1007/s00198-018-4759-3

22. Landfeldt E., Ström O., Robbins S., Borgström F. Adherence to treatment of primary osteoporosis and its association to fractures – the Swedish Adherence Register Analysis (SARA). Osteoporos Int. 2012 Feb;23(2):433-43. doi: 10.1007/s00198-011-1549-6

23. Никитинская О.А., Торопцова Н.В., Насонов Е.Л. Приверженность лечению остеопороза: результаты ретроспективного когортного исследования. Научно-практическая ревматология. 2019;57(4):415-420. doi: 10.14412/1995-4484-2019-415-420.